<i>HER2</i> status and efficay of taxane-based adjuvant therapy of early breast cancer (EBC): a metanalysis of randomized trials involving 7,831 patients.
Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Sabino De Placido, Agnese Montanino(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Valeria Forestieri(University of Naples Federico II), Mario Giuliano(Regione Campania), Carmen Criscitiello(University of Milan), Rossella Lauria, Antonio Giordano(University of Siena)
Cited by 1
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Curcumin and Cancer
|Nutrients|2019|977
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Role of p53 in the Regulation of Cellular Senescence
|Biomolecules|2020|605